3355-21-3

Basic information

• Product Name: 5-Bromo-2-propyl-phenylamine
• Synonyms: 5-Bromo-2-propyl-phenylamine
• CAS NO: 3355-21-3
• Molecular Weight: 214.105
• Mol File: 3355-21-3.mol

Chemical Properties

• CAS DataBase Reference: 5-Bromo-2-propyl-phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-propyl-phenylamine(3355-21-3)
• EPA Substance Registry System: 5-Bromo-2-propyl-phenylamine(3355-21-3)

Safety Data

• Hazardous Substances Data: 3355-21-3(Hazardous Substances Data)

Upstream product

• 3355-08-6 4-Bromo-2-nitro-1-propyl-benzene 
• 103-65-1 phenylpropane 
• 24503-35-3 2,4-dinitro-1-propylbenzene 
• 42411-95-0 4-propyl-3-nitroaniline 
• 7732-18-5 water 

Downstream Products

• 56152-26-2 5-Brom-2-propyl-phenol 
• 92425-68-8 <5-Brom-2-propyl-phenyl>-4-brom-benzolsulfonat 
• 199172-01-5 6-bromo-3-ethyl-1H-indazole 
• 1049651-71-9 1-(6-bromo-3-ethyl-1H-indazol-1-yl)ethanone 

Relevant articles and documents

6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1—R4 A, B, D, E, and G are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS

Therapeutically active compositions of matter are described which are useful for treating or preventing diseases and conditions comprising inflammatory diseases including joint inflammation, Crohn's disease, and inflammatory bowel disease; respiratory dis

Substituted indazole derivatives and related compounds

The invention relates to compounds of the formula I and pharmaceutically acceptable salts thereof, wherein R2aand R2bare independently selected from the group consisting essentially of hydrogen and hereinafter recited substituents, provided that one, but not both of R2aand R2bmust be independently selected as hydrogen, wherein said substituents comprise: wherein the dashed lines in formulas (Ia) and (Ib) independently and optionally represent a single or double bond, provided that in formula (Ia) both dashed lines cannot both represent double bonds at the same time; and R, R1, R3, R4, R5, R6, R7, R18and m are as defined. The invention further relates to intermediates for the preparation of the compounds of formula I, and to pharmaceutical compositions containing, and methods of using, the compounds of formula I, or acceptable salts thereof, for the inhibition of phosphodiesterase (PDE) type IV or the production of tumor necrosis factor (TNF) in a mammal.

Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, R1, and R2, are as defined herein. The invention further relates to pharmaceutical compositions containing, and methods of using, the compounds of formula (I), or acceptable salts thereof, for the inhibition of phosphodiesterase (PDE) type IV or the production of tumor necrosis factor (TNF) in a mammal. The invention also relates to intermediates that are useful in the preparation of the compounds of formula (I).

Substituted indazole analogs

The invention relates to compounds of the formula I and pharmaceutically acceptable salts thereof, wherein R, R1, and R2, are as defined herein. The invention further relates to pharmaceutical compositions containing, and methods of using, the compounds o

Substituted indazole derivatives and related compounds

The invention relates to compounds of the formula I and pharmaceutically acceptable salts thereof, wherein R2a and R2b are independently selected from the group consisting essentially of hydrogen and hereinafter recited substituents, provided that one, bu